Farmer uses $5,000 ram to start conversations about prostate cancer #prostatecancer #awareness #agriculture
@stopthestigma.bsky.social
@stopthestigma.bsky.socialFarmer uses $5,000 ram to start conversations about prostate cancer #prostatecancer #awareness #agriculture
@artera.aiFrom localized to metastatic #ProstateCancer, where can AI-based biomarkers help inform care?
This @Medscape feature explores the growing clinical evidence behind #ArteraAI across the prostate cancer care continuum and beyond.
Read more: buff.ly/QZPlToC
@ancan501c3.bsky.socialTODAY: You're trying to navigate your life AND your disease. Others with a more complex #ProstateCancer, who have been in the same boat, will be there to help in our #virtualsupport group
1st and 3rd Mondays every month at 8pm EST / 5pm PST
@stemcellsciencenews.com📢 New in @cp-cellrepmed.bsky.social: Study findings identify EZH2-PI3K/mTORC1 signaling as a therapeutic vulnerability in phenotypically plastic #ProstateCancer and reveal Tristetraprolin as a contributor to therapy response.
Read the #OpenAccess article here: https://bit.ly/4z8WoQf
@artera.aiThat’s a wrap on #ASTRO26!
Thank you to everyone who connected with the Artera team throughout the meeting. We enjoyed the conversations and the opportunity to spend time with the radiation oncology community.
Until next year! 👋
@evertonthesitcom.bsky.socialPut me on the no view side today, but thats my treatments done until next month now.
Be an early night tonight 🤮
Get checked lads!
@scobb.netThe Graham Fulford Charitable Trust (GFCT) facilitates PSA testing all over the UK.
See: tgfct.org.uk/Testing-and-... #ProstateCancer #PSATests #PSATesting #PCa
@tumorijournal.bsky.social💥 #ProstateCancer A model using simple, routine parameters and PSA doubling time can identify those at minimal risk of reclassification, enabling a safe reduction in #biopsy intensity.
@vcclibrary.bsky.socialThe PSA test for #ProstateCancer screening: an abridged Cochrane review @velindrecc.bsky.social bjui-journals.onlinelibrary.wiley.com/doi/10.1111/...
@healthcaretoday.bsky.socialThe STAMINA trial, the largest of its kind, found that supervised exercise, diet and behavioural support cut fatigue by 30% and improved quality of life by 37% for prostate cancer patients on hormone therapy.
@artera.aiFind us Oct. 8–9 at the Specialty Networks Fall National Conference in Tampa and MSK’s Advances in Prostate Cancer Management in New York.
Reach out to set up a meeting!
@evertonthesitcom.bsky.socialYou know when your bones are on fire, ye that kind of pain.
The joys of side effects, however its a no pain gain attitude from me.
As always, get checked lads!
#prostatecancer
#arghmybonesareonfire
@drtimos.bsky.social🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVkgfk !
@vcclibrary.bsky.socialExternal validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive #ProstateCancer: An analysis of the ARCHES trial. acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
@evertonthesitcom.bsky.socialHere we go again!
Treatment time.
Get checked lads
#prostatecancer
@gmj-georgia.bsky.socialEngineered silica nanoparticles triggered prostate cancer cell death AND supercharged the immune system in mouse studies. Combined … #Immunotherapy #Nanoparticles #Preclinicalresearch #Prostatecancer #Targeteddrugdelivery #Immunotherapy #Nanoparticles #Preclinicalresearch #Prostatecancer #Targe…
@mskcme.bsky.socialJoin us in NYC or virtually on Oct. 8–9 to explore advances and key questions across the continuum of #ProstateCancer care, featuring tumor boards, panel discussions, and debates with multidisciplinary experts from @mskcancercenter.bsky.social and other leading institutions. 🔗 bit.ly/Prostate2026CME
@jco-asco.bsky.socialCan early #ctDNA kinetics tell us more than PSA alone in #mCRPC?
This review examines ctDNA across ARPIs, chemotherapy, PARP inhibitors & PSMA-targeted radioligand therapy.
Read about the findings. https://bit.ly/4hepzeK
#ProstateCancer #LiquidBiopsy
@dalton-liuxz.bsky.socialIntegrating single-cell imaging, multi-omics analyses, mechanistic studies, therapeutic modeling & a Phase Ib trial, our study identifies BCL-2 as a therapeutic vulnerability across heterogeneous CRPC.
Congrats to Anmbreen Jamroze, Dean G. Tang, Gurkamal Chatta & our team!
#ProstateCancer #BCL2